Life science company Chiral Quest this week announced that the non-profit organisation, the Penn State Research Foundation, has received a US patent covering the compositions of matter and use for a series of chiral phosphine ligands and catalysts with ferrocene backbones.
Palladium-complexes form catalysts for allylic alkylations and Silver (I)-complexes form efficient catalysts for asymmetric [3 + 2] cyclisation reactions. According to Chiral Quest, the key features of this family of ligands are their air stable solid composition and high electron donating capacity.
"I am delighted that our patent estate is solidifying," commented Alan Roth CEO of Chiral Quest. "This gives us a further edge for business development and I am confident that our proprietary chiral ligands are on the forefront of technology in the catalysis space."
The inventor of the patent, Professor Xumu Zhang, chief technology officer at Chiral Quest, added :"This patent (No. 6,534,657) discloses some effective methods for making carbon-carbon bonds, which is potentially usefully to prepare an array of biologically active drug-like chiral molecules."
Ferrocene phosphines are the fifth family of ligands to be added to Chiral Quest's patent portfolio.